MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Inicio・Lista de Acciones・Avita Therapeutics Inc

Avita Therapeutics Inc

Cerrado

5.12 3.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.97

Máximo

5.23

Métricas clave
By Trading Economics
Ingresos	1.6M -12M
Ventas	554K 18M
Margen de beneficios	-65.968
Empleados	226
EBITDA	1.6M -9.7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+26.85% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	27M 150M
Apertura anterior	2.1
Cierre anterior	5.12

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.83 / 9.77 Soporte y Resistencia

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 abr 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 abr 2026, 18:15 UTC

Noticias de Eventos Importantes

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 abr 2026, 22:58 UTC

Ganancias

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 abr 2026, 21:32 UTC

Charlas de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 abr 2026, 20:52 UTC

Ganancias

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 abr 2026, 20:29 UTC

Ganancias

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 abr 2026, 20:11 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 abr 2026, 19:34 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

17 abr 2026, 19:34 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 abr 2026, 19:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 abr 2026, 19:26 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 abr 2026, 19:21 UTC

Charlas de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 abr 2026, 19:15 UTC

Charlas de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 abr 2026, 19:07 UTC

Charlas de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 abr 2026, 18:57 UTC

Noticias de Eventos Importantes

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB 2026 Rev Guidance Unchanged

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 abr 2026, 18:14 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 abr 2026, 17:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 abr 2026, 17:26 UTC

Charlas de Mercado

Ganancias

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

26.85% repunte

Estimación a 12 Meses

Media 6.33 USD 26.85%

Máximo 10 USD

Mínimo 3.5 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Avita Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.